Cutaneous adverse events caused byimmune checkpoint inhibitors:classification and management
10.3760/cma.j.issn.1004-4221.2018.03.021
- VernacularTitle:肿瘤免疫检查点抑制剂治疗不良反应及其治疗——皮肤
- Author:
Fangfang NIE
1
;
Jie FU
Author Information
1. 200233,上海交通大学附属第六人民医院肿瘤放疗科
- Keywords:
immune checkpoint inhibitors;
immune-related adverse events;
cutaneous adverse events
- From:
Chinese Journal of Radiation Oncology
2018;27(3):331-334
- CountryChina
- Language:Chinese
-
Abstract:
Immune checkpoint inhibitors(ICPIs)have been successfully used in the treatment of multiple malignancies.However,immune-related adverse events(irAEs)may occur during treatment.Cutaneous adverse event(CAE)is acommon type of irAE. Mild CAEs include maculopapule,lichenoid reaction,bullous pemphigoid,vitiligo,psoriasis,and scleroderma. Severe and even life-threatening CAEs include Steven-Johnson syndromeand toxic epidermal necrolysis. Other CAEs include drug reactionwith eosinophiliaand systemic symptoms,Sweet′s syndrome,alopecia,Grover′s disease, and paraneoplastic syndrome. This paper reviews the treatment of cutaneous adverse events associated with ICPIs.
